Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80.
Shahbandi A, Chiu FY, Ungerleider NA, Kvadas R, Mheidly Z, Sun MJS, Tian D, Waizman DA, Anderson AY, Machado HL, Pursell ZF, Rao SG, Jackson JG.
Shahbandi A, et al. Among authors: machado hl.
Nat Cancer. 2022 Dec;3(12):1513-1533. doi: 10.1038/s43018-022-00466-y. Epub 2022 Dec 8.
Nat Cancer. 2022.
PMID: 36482233
Free PMC article.